Mechanisms of Action Involved in Ozone Therapy: Is healing induced via a mild oxidative stress?

Masaru Sagai, Velio Bocci, Masaru Sagai, Velio Bocci

Abstract

The potential mechanisms of action of ozone therapy are reviewed in this paper. The therapeutic efficacy of ozone therapy may be partly due the controlled and moderate oxidative stress produced by the reactions of ozone with several biological components. The line between effectiveness and toxicity of ozone may be dependent on the strength of the oxidative stress. As with exercise, it is well known that moderate exercise is good for health, whereas excessive exercise is not.Severe oxidative stress activates nuclear transcriptional factor kappa B (NFκB), resulting in an inflammatory response and tissue injury via the production of COX2, PGE2, and cytokines. However, moderate oxidative stress activates another nuclear transcriptional factor, nuclear factor-erythroid 2-related factor 2 (Nrf2). Nrf2 then induces the transcription of antioxidant response elements (ARE). Transcription of ARE results in the production of numerous antioxidant enzymes, such as SOD, GPx, glutathione-s-transferase(GSTr), catalase (CAT), heme-oxygenase-1 (HO-1), NADPH-quinone-oxidoreductase (NQO-1), phase II enzymes of drug metabolism and heat shock proteins (HSP). Both free antioxidants and anti-oxidative enzymes not only protect cells from oxidation and inflammation but they may be able to reverse the chronic oxidative stress. Based on these observations, ozone therapy may also activate Nrf2 via moderate oxidative stress, and suppress NFκB and inflammatory responses. Furthermore, activation of Nrf2 results in protection against neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Mild immune responses are induced via other nuclear transcriptional factors, such as nuclear factor of activated T-cells (NFAT) and activated protein-1 (AP-1).Additionally, the effectiveness of ozone therapy in vascular diseases may also be explained by the activation of another nuclear transcriptional factor, hypoxia inducible factor-1α (HIF-1a), which is also induced via moderate oxidative stress. Recently these concepts have become widely accepted. The versatility of ozone in treating vascular and degenerative diseases as well as skin lesions, hernial disc and primary root carious lesions in children is emphasized. Further researches able to elucidate whether the mechanisms of action of ozone therapy involve nuclear transcription factors, such as Nrf2, NFAT, AP-1, and HIF-1α are warranted.

Figures

Figure 1
Figure 1
Figure 2
Figure 2

References

    1. Wolff HH. Die Behandlung peripherer Durchbutungsstorungen mit Ozon. Erfahr Hk. 1974;23:181–184.
    1. Nakao A, Sugimoto R, Billiar TR, McCurry KR. Therapeutic antioxidant medical gas. J Clin Biochem Nutr. 2009;44:1–13.
    1. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109–142.
    1. Morse D, Sethi J, Choi AM. Carbon monoxide-dependent signaling. Crit Care Med. 2002;30:S12–17.
    1. Calvert JW, Jha S, Gundewar S, Elrod JW, Ramachandran A, Pattillo CB, Kevil CG, Lefer DJ. Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ Res. 2009;105:365–374.
    1. Xu ZS, Wang XY, Xiao DM, Hu LF, Lu M, Wu ZY, Bian JS. Hydrogen sulfide protects MC3T3-E-1 osteoblastic cells against H2O2-induced oxidative damage-implications for the treatment of osteoporosis. Free Radic Biol Med. 2011;50:1314–1323.
    1. Jolly D, Meyer J. A brief review of radiation hormesis. Australas Phys Eng Sci Med. 2009;32:180–187.
    1. Calabrese EJ. Hormesis is central to toxicology, pharmacology and risk assessment. Hum Exp Toxicol. 2010;29:249–61.
    1. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW, Weindruch R. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009;325:201–204.
    1. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, Gorospe M, de Cabo R, Sinclair DA. Caloric restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science. 2004;305:390–392.
    1. Pryor WA, Squadrito GL, Friedman M. The cascade mechanism to explain ozone toxicity: the role of lipid ozonation products. Free Radic Biol Med. 1995;19:935–941.
    1. Shimasaki H, Takatori T, Anderson WR, Horten HL, Privett OS. Alteration of lung lipids in ozone exposed rats. Biochem Biophys Res Commun. 1976;68:1256–1262.
    1. Dianzani MUl. 4-Hydroxynonenal and cell signaling. Free Radi Res. 1998;28:553–560.
    1. Page S, Fischer C, Baumqartner B, Haas M, Kreusel U, Loidl G, Hayn M, Ziegler-Heitbrock HW, Neumeier D, Brand K. 4-Hydroxynonenal prevents NFκB activation and tumor necrosis factor expression by inhibiting IκB phosphorylation and subsequent proteolysis. J Biol Chem. 1999;274:11611–11618.
    1. Groeger G, Quiney C, Cotter TG. Hydrogen peroxide as a cell-survival signaling molecule. Antioxid Redox Signal. 2009;11:2655–2671.
    1. Hao Q, Rutherford SA, Low B, Tang H. Selective regulation of hydrogen peroxide signaling by receptor tyrosine phosphatase-alpha. Free Radic Biol Med. 2006;41:302–310.
    1. Lin CC, Lee IT, Yang YL, Lee CW, Kou YR, Yang CM. Induction of COX-2/PGE2/IL-6 is crucial for cigarette smoke extract-induced airway inflammation: role of TLR4 -dependent NADPH oxidase activation. Free Radic Biol Med. 2010;48:240–254.
    1. Williams AS, Leung SY, Nath P, Khorasani NM, Bhavsar P, Issa R, Mitchell JA, Adcock IM, Chung KF. Role of TLR2, TLR4, and MyD88 in murine ozone-induced airway hyperresponsiveness and neutrophilia. J Appl Physiol. 2007;103:1189–1195.
    1. Lippman M. Health effects of ozone, a critical review. J Am Air Pollut Control Assoc. 1989;39:672–695.
    1. Bhalla DK, Gupta SK. Lung injury, inflammation, and inflammatory stimuli in rats exposed to ozone. J Toxicol Environ Health. 2000;59:211–228.
    1. Jerrett M, Burnett RT, Pope CA, Ito K, Thurston G, Krewski D, Shi Y, Calle E, Thun M. Long-term ozone exposure and mortality. N Engl J Med. 2009;360:1085–1095.
    1. Valacchi G, Pagnin E, Corbacho AM, Olano E, Davis PA, Packer L, Cross CE. In vivo ozone exposure induces antioxidant/stress-related responses in murine lungs and skin. Free Radic Biol Med. 2004;36:673–681.
    1. Valacchi G, Fortino V, Bocci V. The dual action of ozone on the skin. Br J Dermatol. 2005;153:1096–1100.
    1. Wentworth P Jr, McDunn JE, Wentworth AD, Takeuchi C, Nieva J, Jones T, Bautista C, Ruedi JM, Gutierrez A, Janda KD, Babior BM, Eschenmoser A, Lerner RA. Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. Science. 2002;298:2195–99.
    1. Yamashita K, Miyoshi T, Arai T, Endo N, Itoh H, Makino K, Mizugishi K, Uchiyama T, Sasada M. Ozone production by amino acids contributes to killing of bacteria. Proc Natl Acad Sci, USA. 2008;105:16912–7.
    1. Bastacky J, Lee CY, Goerke J, Koushafar H, Yager D, Kenaga L, Speed TP, Chen Y, Clements JA. Alveolar lining layer is thin and continuous: low temperature scanning electron microscopy of rat lung. J Appl Physiol. 1995;79:1615–1628.
    1. Mustafa MG. Biochemical basis of ozone toxicity. Free Radic Biol Med. 1990;9:245–265.
    1. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11:81–128.
    1. Schaur RJ. Basic aspects of the biochemical reactivity of 4-hydroxynonenal. Mol Aspects Med. 2003;24:149–159.
    1. Pulfer MK, Taube C, Gelfand E, Murphy RC. Ozone exposure in vivo and formation of biologically active oxysterols in the lung. J Pharmacol Exp Ther. 2005;312:256–264.
    1. Sathishkumar K, Haque M, Perumal TE, Francis J, Uppu RM. A major ozonation product of cholesterol, 3-beta-hydroxy-5-oxo-5,6-secocholestan- 6-al, induces apoptosis in H9c2 cardiomyoblasts. FEBS Lett. 2005;579:6444–6450.
    1. Mendiratta S, Qu ZC, May JM. Erythrocyte ascorbate recycling: antioxidant effects in blood. Free Radic Biol Med. 1998;24:789–797.
    1. Crapo JD. Morphologic changes in pulmonary oxygen toxicity. Ann Rev Physiol. 1986;48:721–731.
    1. Ruidavets JB, Cournot M, Cassadou S, Giroux M, Meybeck M, Ferrieres J. Ozone air pollution is associated with acute myocardial infarction. Circulation. 2005;111:563–569.
    1. Tager IB, Balmes J, Lurmann F, Ngo L, Alcorn S, Kunzli N. Chronic exposure to ambient ozone and lung function in young adults. Epidemiology. 2005;16:751–759.
    1. Aris RM, Christian D, Hearne PQ, Kerr K, Finkbeiner WE, Balmes JR. Ozone-induced airway inflammation in human subjects as determined by airway lavage and biopsy. Am Rev Respir Dis. 1993;148:1363–1372.
    1. Spickett CM, Jerlich A, Panasenko OM, Arnhold J, Pitt AR, Stelmaszynska T, Schaur RI. The reactions of hypochlorous acid, the reactive oxygen species produced by myeloperoxidase, with lipids. Acta Biochem Pol. 2000;47:889–899.
    1. Bocci V. Is it true that ozone is always toxic? The end of the dogma. Toxicol Appl Pharmacol. 2006;216:493–504.
    1. Zhang W, He Q, Chan LL, Zhou F, El Naghy M, Thompson EB, Ansari NH. Involvement of caspases in 4-hydroxy-alkenal induced apoptosis in human leukemic cells. Free Radic Biol Med. 2001;30:699–706.
    1. Choudhary S, Zhang W, Zhou F, Campbell GA, Chan LL, Thompson EB, Ansari NH. Cellular lipid peroxidation end-products induce apoptosis in human lens epithelial cells. Free Radic Biol Med. 2002;32:360–369.
    1. Larini A, Bianchi L, Bocci V. Effect of 4-hydroxynonenal on antioxidant capacity and apoptosis induction in Jurkat T cells. Free Radic Res. 2004;38:509–516.
    1. Awasthi YC, Ansari GA, Awasthi S. Regulation of 4-hydroxynonenal mediated signaling by glutathione S-transferases. Methods Enzymol. 2005;401:379–407.
    1. Iles KE, Dickinson DA, Wigley AF, Welty NE, Blank V, Forman HJ. HNE increases HO-1 through activation of the ERK pathway in pulmonary epithelial cells. Free Radic Biol Med. 2005;39:355–364.
    1. Barrera G, Pizzimenti S, Dianzani MU. 4-hydroxynonenal and regulation of cell cycle: effects on the pRb/E2F pathway. Free Radic Biol Med. 2004;37:597–606.
    1. Bocci V, Borrelli E, Valacchi G, Luzzi E. Quasi-total-body exposure to an oxygen-ozone mixture in a sauna cabin. Eur J Appl Physiol Occup Physiol. 1999;80:549–554.
    1. Bocci V. Ozone A new medical drug. 2. Dordrecht, The Netherlands: Springer Publ; 2011.
    1. Poli G, Schaur RJ. 4-Hydroxynonenal in the pathomechanisms of oxidative stress. IUBMB Life. 2000;50:315–321.
    1. Chiarpotto E, Castello L, Leonarduzzi G, Biasi A, Poli G. Role of 4-hydroxy-2,3-nonenal in the pathogenesis of fibrosis. BioFactors. 2005;24:229–236.
    1. Bocci V, Valacchi G, Corradeschi F, Aldinucci C, Silvestri S, Paccagnini E, Gerli R. Studies on the biological effects of ozone. 7. Generation of reactive oxygen species (ROS) after exposure of human blood to ozone. J Biol Regul Homeost Agents. 1998;12:67–75.
    1. Bocci V. Oxygen-ozone Therapy A Critical Evaluation. Dordrecht, The Netherlands, Kluwer Academic Publishers; 2002.
    1. Stone JR, Collins T. The role of hydrogen peroxide in endothelial proliferative responses. Endothelium. 2002;9:231–238.
    1. Bocci V, Aldinucci C. The use of hydrogen peroxide as a medical drug. Riv Ital Ossigeno-Ozonoter. 2005;4:30–39.
    1. Goldstein BD, Balchum OJ. Effect of ozone on lipid peroxidation in the red blood cell. Proc Soc Exp Biol Med. 1967;126:356–359.
    1. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Methods Enzymol. 1994;234:279–293.
    1. Travagli V, Zanardi I, Silvietti A, Bocci V. A physicochemical investigation on the effects of ozone on blood. Int J Biol Macromol. 2007;41:504–511.
    1. Bocci V. Scientific and medical aspects of ozone therapy, State of the art. Arch Med Res. 2006;37:425–435.
    1. Bocci V. The case for oxygen-ozonetherapy. Br J Biomed Sci. 2007;64:44–47.
    1. Bocci V, Borrelli E, Travagli V, Zanardi I. The ozone paradox: Ozone is a strong oxidant as well as a medical drug. Medicinal Res Rev. 2009;29:646–682.
    1. Bocci V, Borrelli E, Corradeschi F, Valacchi G. Systemic effects after colorectal insufflation of oxygen-ozone in rabbits. Int J Med Biol Environ. 2000;28:109–113.
    1. Alary J, Geuraud F, Cravedi JP. Fate of 4-hydroxynonenal in vivo: disposition and metabolic pathways. Mol Aspects Med. 2003;24:177–187.
    1. Siems W, Grune T. Intracellular metabolism of 4-hydroxynonenal. Mol Aspects Med. 2003;24:167–175.
    1. Bocci V. Does ozone therapy normalize the cellular redox balance ? Med Hypotheses. 1996;46:150–154.
    1. Zhang H, Liu H, Iles KE, Liu RM, Postlethwait EM, Laperche Y, Forman HI. 4-hydroxynonenal induces rat gamma-glutamyl transpeptidase through mitogen-activated protein kinase-mediated electrophile response element/nuclear factor erythroid 2-related factor 2 signaling. Am J Respir Cell Mol Biol. 2006;34:174–181.
    1. Takahashi Y, Takahashi S, Yoshimi T, Miura T, Mochitate K, Kobayashi T. Increase in the mRNA levels of γ-glutamyl-transferase and heme-oxygenase-1 in the rat lung after ozone exposure. Biochem Pharmacol. 1997;53:1061–1064.
    1. Chen JZ, Sharma R, Yang Y, Singhal SS, Sharma A, Saini MK, Singh SV, Zimniak P, Awasthi S, Awasthi YC. Accelerated metabolism and exclusion of 4-hydroxynonenal through induction of RLIP 76 and hGST 5.8 is an early adaptive response of cells to heat and oxidative stress. J Biol Chem. 2001;276:41213–41223.
    1. Forman HJ, Dickinson DA, Iles KE. HNE-signaling pathways leading to its elimination. Mol Aspects Med. 2003;24:189–194.
    1. Yamamoto Y. Fate of lipid hydroperoxide in blood plasma. Free Radic Res. 2000;33:795–800.
    1. Xu C, Huang MT, Shen G, Lin W, Khor TO, Conney AH, Kong AN. Inhibition of 7,12-dimethylbenzo(a) -anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res. 2006;66:8293–8296.
    1. Li W, Khor TO, Xu C, Shen G, Jeong WS, Yu S, Kong AN. Activation of Nrf2-antioxidant signaling attenuates NF kappa B-inflammatory response and elicits apotosis. Biochem Pharmacol. 2008;76:1485–1489.
    1. Kwak MK, Kensler TW. Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol. 2010;244:66–76.
    1. Gomez-Cabrera MC, Domenech E, Vina J. Moderate exercise is an antioxidant: Upregulation of antioxidant genes by traning. Free Radic Biol Med. 2008;44:126–131.
    1. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y. An Nrf2/small Maf heterodimer mediate the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997;236:313–322.
    1. Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med. 2004;10:549–557.
    1. Dinkova-Kostova AT. Phytochemicals as protectors against ultraviolet radiation: Versatility of effects and mechanisms. Planta Med. 2008;74:1548–1559.
    1. Brunt KB, Fenrich KK, Kiani G. Protection of human vascular smooth muscle cells from H2O2-induced apoptosis through functional codependence between HO-1 and AKT. Arterioscler Thromb Vasc Biol. 2006;26:2027–2034.
    1. He X, Lin GX, Chen MG, Zhang JX, Ma Q. Protection against chromium (VI)-induced oxidative stress and apoptosis by Nrf2 into the nucleus and disrupting the nuclear Nrf2/Keap 1 association. Toxicol Sci. 2007;98:298–309.
    1. Khodagholi F, Tusi SK. Stability of Nrf2 by tBHQ prevents LPS-induced apoptosis in differentiated PC12 cells. Mol Cell Biochem. 2011;354:97–112.
    1. Villeneuve NF, Sun Z, Chen W, Zhang DD. Nrf2 and p21 regulate the fine balance between life and death by controlling ROS levels. Cell Cycle. 2009;8:3255–3256.
    1. Slocum SL, Kensler TW. Nrf2: control of sensitivity to carcinogens. Arch Toxicol. 2011;85:272–284.
    1. Martin-Montalvo A, Villalba JM, Navas P, de Cabo R. NRF2, cancer and calorie restriction. Oncogene. 2011;30:505–520.
    1. Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR, Chen PC. The Nrf2-ARE pathway: An indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci. 2008;1147:61–69.
    1. Jazwa A, Cuadrado A. Targeting heme oxygenase-1 for neuroprotection and neuroinflammation in neurodegenerative diseases. Curr Drug Targets. 2010;11:1517–1531.
    1. Bocci V, Travagli V, Zanardi I. May oxygen-ozone therapy improves cardiovascular disorders ? Cardiovascular & Haematological Disorders-Drug Targets. 2009;9:78–85.
    1. Bocci V, Zanardi I, Travagli V. Ozone: a new medical drug in vascular diseases. Am J Cardiovas Drugs. 2011;11:73–82.
    1. Li J, Ichikawa T, Janichi JS, Cui T. Targeting the Nrf2 pathway against cardiovascular disease. Expert Opin Ther Targets. 2009;13:785–794.
    1. Ishii Y, Morishima Y, Kimura T, Kimura T, Kiwamoto T, Iizuka T, Hegab AE, Hosoya T, Nomura A, Sakamoto T, Yamamoto M, Sekizawa K. Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J Immunol. 2005;175:6968–6975.
    1. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49:1603–1616.
    1. Singh S, Vrishni S, Singh BK, Rahman I, Kakkar P. Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory disease. Free Radic Res. 2010;44:1267–1288.
    1. Li M, Fukagawa NK. Age-related changes in redox signaling and VSMC function. Antioxid Redox Signal. 2010;12:641–655.
    1. Rokitansky O. Klinik und biochemie der ozonotherapie. Hospitalis. 1982;52:643–647.
    1. Bocci V, Larini A, Micheli V. Restoration of normoxia by ozonetherapy may control neoplastic growth: A review and a working hypothesis. J Altern Complem: Med. 2005;11:257–265.
    1. Travagli V, Zanardi I, Bernini P, Nepi S, Tenori L, Bocci V. Effects of ozone blood treatment on the metabolite profile of human blood. Intern J Toxicol. 2010;29:165–174.
    1. Bocci V, Di Paolo N. Oxygenation-ozonation of blood during extracorporeal circulation (EBOO). Part III: a new medical approach. Ozone Sci Eng. 2004;26:195–205.
    1. Di Paolo N, Bocci V, Salvo DP, Palasciano G, Biagioli M, Meini S, Galli F, Ciari I, Maccari F, Cappelletti F, Di Paolo M, Gaggiotti E. Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. Int J Artif Organs. 2005;28:1039–1050.
    1. Bocci V, Aldinucci C, Mosci F, Carraro F, Valacchi G. Ozonation of human blood induces a remarkable upregulation of heme oxygenase-1 and heat stress protein-70. Mediators Inflamm. 2007. Article ID 26785.
    1. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Pro Natl Acad Sci USA. 1995;92:5510–5514.
    1. Siddiq A, Aminova LR, Ratan RR. Prolyl 4-hydroxylase activity-responsive transcription factors: From hydroxylation to gene expression and neuroprotection. Front Biosci. 2008;13:2875–2887.
    1. Siddiq A, Aminova LR, Ratan RR. Hypoxia inducible factor prolyl 4-hydroxylase enzymes: Center stage in the battle against hypoxia, metabolic compromise and oxidative stress. Neurochem Res. 2007;32:931–946.
    1. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, Garcia JG, Semenza GL. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood. 2005;105:659–669.
    1. Morsy MD, Hassan WN, Zalat SI. Improvement of renal oxidative stress markers after ozone administration in diabetic nephropathy in rats. Diabeteol Metabol Syndr. 2010;2:29–35.
    1. Martınez-Sanchez G, Al-Dalain SM, Menendez S, Re L, Giuliani A, Candelario-Jalil E, Alvarez H, Fernández-Montequín JI, León OS. Therapeutic efficacy of ozone in patients with diabetic foot. Eur J Pharmacol. 2005;523:151–161.
    1. Bocci V, Zanardi I, Michaeli V, Travagli V. Mechanisms of action and chemical-biological interactions between ozone and body compartments: a critical appraisal of the different administration routes. Current Drug Therapy. 2009;4:159–173.
    1. Eliakim R, Karmeli F, Rachmilewitz D. Ozone enema: a model of microscopic colitis in rats. Dig Dis Sci. 2001;46:2515–2520.
    1. Bocci V, Zanardi I, Huijberts MSP, Travagli V. Diabetes and chronic oxidative stress. A perspective based on the possible usefulness of ozone therapy. Diabe Metabo Syndr: Clinical Research and Reviews. 2011;5:45–49.
    1. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27:591–619.
    1. Amasaki Y. Calcineurin inhibitors and calcineurin-NFAT system. Nihon Rinsyo Meneki Gakkai Kaishi (Jpn J Clin Immunol) 2010;33:249.
    1. Kaminuma O. Selective inhibitors of nuclear factor of activated T cells: potencial therapeutic drugs for the treatment of immunological and inflammatory diseases. Inflamm Allergy Drug Targets. 2008;7:35–40.
    1. Maziere C, Morliere P, Louandre C, Conte MA, Gomilla C, Santus R, Antonicelli F, Hornebeck W, Mazière JC. Low UVA doses activate the transcription factor NFAT in human fibroblasts by a calcium-calcinurin pathway. Free Radic Biol Med. 2005;39:1629–1637.
    1. Bocci V, Paulesu L. Studies on the biological effects of ozone 1. Induction of interferon gamma on human leukocytes. Haematologica. 1990;75:510–515.
    1. Bocci V, Luzzi E, Corradeschi F, Paulesu L, Di Stefano A. Studies on the biological effects of ozone 4. An attempt to define conditions for optimal induction of cytokines. Lymphokine Cytokine Res. 1993;12:121–126.
    1. Bocci V, Valacchi G, Corradeschi F, Fanetti G. Studies on the biological effects of ozone 8. Effects on the total antioxidant status and on interleukin-8 production. Mediators Inflamm. 1998;7:313–317.
    1. Bocci VA, Zanardi I, Travagli V. Ozone acting on human blood yields a hormetic dose-response relationship. J Translational Medicine. 2011;9:66–76.
    1. Burgassi S, Zanardi I, Travagli V, Montomoli E, Bocci V. How much ozone bactericidal activity is compromised by plasma components ? J.Appl Microbiol. 2009;106:1715–1721.
    1. Bocci V, Venturi G, Catucci M, Valensin PE, Zazzi M. Lack of efficacy of ozone therapy in HIV infection. Clin Microbiol Infec. 1998;4:667–669.
    1. Sweet F, Kao MS, Lee S. Ozone selectively inhibits growth of human cancer cells. Science. 1980;209:931–933.
    1. Schulz S, Haussler U, Mandic R, Heverhagen JT, Neubauer A, Dünne AA, Werner JA, Weihe E, Bette M. Treatment with ozone/oxygen-pneumoperitoneum results in complete remmision of rabbit squamous cell carcinomas. Int J Cancer. 2008;122:2360–2367.
    1. Bocci V. Does ozone really "cure" cancer ? Int J Cancer. 2008;123:1222.
    1. Kwak MK, Kensler TW. Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol. 2010;244:66–76.
    1. Tufekci KU, Civi Bathway E, Genc S, Genc K. The Nrf2/ARE pathway: A promising target to counteract mitochondrial dysfunction in Parkinson's disease. Parkinson's disease; 2011. in press .
    1. Idriss NK, Blann AD, Lip GY. Hemoxygenase-1 in cardiovascular disease. J Am Coll Cardiol. 2008;52:971–978.
    1. Scapagnini G, Sonya V, Nader AG, Zella D, Fabio G. Modulation of Nrf2/ARE pathway by food polyphenols: A nutritional neuroprotective strategy for cognitive and neurodegerative disorders. Mol Neurobiol. 2011. in press .
    1. Kweon MH, Adhami VM, Lee JS, Mukhtar H. Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A459 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J Biol Chem. 2006;44:33761–33772.
    1. Neymotin A, Calingasan NY, Wille E, Naseri N, Petri S, Damiano M, Liby KT, Risingsong R, Sporn M, Beal MF, Kiaei M. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethlamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med. 2011;51:88–96.
    1. Son TG, Camandola S, Mattson MP. Hormetic dietary phytochemicals. Neuromolecul Med. 2008;10:236–46.
    1. Miura T, Iwai A, Tamoto K, Yamazaki A, Nochi H. Components and ant-inflammatory action mechanism of ozonized olive oil. In Proceeding of 19th Ozone World Congress of the IOA: Aug31-Sep3 2009; Tokyo; pp. 145–166.
    1. Valacchi G, Lim Y, Belmonte G, Miracco C, Zanardi I, Bocci V, Travagli V. Ozonated sesame oil enhances cutaneous wound healing in SKH1 mice. Wound Reapir Regener. 2010;19:107–115.
    1. Travagli V, Zanardi I, Bocci V. Topical application of ozone and ozonated oils as anti-infective agents: an insight into the patent claims. Recent Patents on Anti-Infective Drug Discovery. 2009;4:130–142.
    1. Travagli V, Zanardi I, Valacchi G, Bocci V. Ozone and ozonated oils in skin diseases: a review. Mediators Inflamm. 2010. (2010 Article ID 610418, EPUB 2010) July 4, Review.
    1. Andreula CF, Simonetti L, De Santis F, Agati R, Ricci R, Leonardi M. Minimally invasive oxygen-ozone therapy for lumbar disk herniation. Am J Neuroradiol. 2003;24:996–1000.
    1. Bocci V, Pogni R, Corradeschi F, Busu E, Cervelli C, Bocchi L, Basosi R. Oxygen-ozone in orthopaedics: EPR detection of hydroxyl free radicals in ozone-treated "nucleus pulposus" material. Riv Neuroradiol. 2001;14:55–59.
    1. Bocci V, Bianchi L, Larini A. The ozone enigma in medicine. The biochemical relationship between ozone and body fluids may account for its biological, therapeutic and toxic effects. Riv Ital Ossigeno-Ozonoterapia. 2003;2:113–120.
    1. Lynch E. Ozone: The Revolution in Dentistry. Copenhagen, Quintessence books; 2004.
    1. Chandiramani N, Wang X, Margeta M. Molecular basis for vulnerability to mitochondrial and oxidative stress in a neuroendocrine CR1-G1 cell line. PloS One. 2011;6 in press.
    1. Bocci V, Zanardi I, Travagli V. Oxygen/ozone as a medical gas mixture. A critical evaluation of the various methods clarifies positive and negative aspects. Medical Gas Research. 2011;1:6.
    1. Jacobs MT. Untersuchung uber Zwischendalle und typische Komplikationen in der ozon-Sauersoff - Therapie. OzoNachrichten. 1982;1:5.
    1. Bocci V, Zanardi I, Travagli V. Potentiality of oxygen-ozone therapy to improve the health of aging people. Curr Aging Sci. 2010;3:177–187.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi